Insights From the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study Part II: Gender Differences in Presentation, Diagnosis, and Outcome With Regard to Gender-Based Pathophysiology of Atherosclerosis and Macrovascular and Microvascular Coronary Disease by Bairey Merz, C. Noel et al.
I
I
P
W
M
C
V
C
W
A
L
B
I
d
a
t
a
w
b
a
i
p
s
c
‡
P
M
D
P
I
A
s
C
G
M
B
6
R
G
G
S
L
2
Journal of the American College of Cardiology Vol. 47, No. 3 Suppl S
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
Pnsights From the NHLBI-Sponsored Women’s
schemia Syndrome Evaluation (WISE) Study
art II: Gender Differences in Presentation, Diagnosis, and Outcome
ith Regard to Gender-Based Pathophysiology of Atherosclerosis and
acrovascular and Microvascular Coronary Disease
. Noel Bairey Merz, MD, FACC,* Leslee J. Shaw, PHD,* Steven E. Reis, MD, FACC,†
era Bittner, MD, FACC,# Sheryl F. Kelsey, PHD,‡ Marian Olson, MS,‡ B. Delia Johnson, PHD,‡
arl J. Pepine, MD, MACC,§ Sunil Mankad, MD, FACC, Barry L. Sharaf, MD, FACC,¶
illiam J. Rogers, MD, FACC,# Gerald M. Pohost, MD, FACC,** Amir Lerman, MD, FACC,††
rshed A. Quyyumi, MD, FACC,‡‡ George Sopko, MD,§§ for the WISE Investigators
os Angeles, California; Pittsburgh, Pennsylvania; Gainesville, Florida; Providence, Rhode Island;
irmingham, Alabama; Rochester, Minnesota; Atlanta, Georgia; and Bethesda, Maryland
Coronary heart disease is the leading cause of death and disability in the U.S., but recent
advances have not led to declines in case fatality rates for women. The current review
highlights gender-specific issues in ischemic heart disease (IHD) presentation, evaluation,
and outcomes with a special focus on the results derived from the National Institutes of
Health-National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome
Evaluation (WISE) study. In the second part of this review, we will assess new evidence on
gender-based differences in vascular wall or metabolic alterations, atherosclerotic plaque
deposition, and functional expression on worsening outcomes of women. Additionally,
innovative cardiovascular imaging techniques will be discussed. Finally, we identify critical
areas of further inquiry needed to advance this new gender-specific IHD understanding into
improved outcomes for women. (J Am Coll Cardiol 2006;47:21S–9S) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.12.084American College of Cardiology Foundation
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mn part II of this review, we will further define gender
ifferences in clinical presentation, disease pathophysiology,
nd clinical outcome as well as outline important next steps
oward improved detection, assessment, and treatment
imed at improving outcomes in women. For this section,
e will attempt to further define the complexity of risk-
ased models that intertwine with our traditional diagnostic
ssessments with new evidence on gender-based differences
n vascular wall or metabolic alterations and atherosclerotic
laque deposition and functional expression on worsening
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004, accepted December 20, 2004.utcomes of women (1). We will start our discussion by
ocusing on the role of differential symptoms and coronary
isease incidence and prevalence on medical resource utili-
ation patterns between women and men.
ENDER DIFFERENCES IN ISCHEMIC HEART DISEASE
IHD) PRESENTATION, EVALUATION, AND OUTCOMES
aps in medical resource utilization have frequently been
eported as “gender bias” in diagnosis or treatment, as noted
rom observational and administrative databases, causing
onsiderable controversy about the adequacy of cardiovas-
ular care for women, in particular for female ethnic
inority subsets of the population (2–12). Recent contro-
ersy extends prior work, noting not only an underuse of
edical services in women but also an overuse or use
ithout adequate clinical indications for male patients (13).
hese reports have had an impact upon referral patterns, as
arly reports of procedural underuse in women have resulted
n recent trends toward an increasing referral of female
opulations to surgical revascularization (14).
The gender-specific difference in cardiovascular disease
ortality provides additional support for a lack of compa-
able progress in population-based risk reduction efforts for
omen. Since 1984, the total number of deaths from
ardiovascular disease has been greater for women as com-
ared with men (2). In the year 2000, approximately 60,000
ore women than men died from cardiovascular disease.
lthough recent reports on age-adjusted coronary heart
d
s
d
f
r
d
n
a
i
p
c
t
c
u
u
e
t
m
(
n
s
h
r
t
p
h
g
d
s
d
l
f
e
(
i
s
A
D
h
s
(
p
(
a
r
a
c
b
c
G
S
R
a
i
m
t
i
(
s
r
n
n
fi
c
m
F
t
w
c
a
c
l
m
P
T
f
1
e
a
d
s
t
t
w
g
d
v
t
(
p
d
a
w
c
22S Bairey Merz et al. JACC Vol. 47, No. 3 Suppl S
The WISE Study: Microvascular and Macrovascular Disease February 7, 2006:21S–9Sisease mortality rates noted an approximately 50% decline
ince peaking in the 1960s, substantively reduced rates of
ecline were observed in lower socioeconomic, racial, and
emale subsets of the population (14,15). Moreover, in a
ecent report from the Olmstead county registry, marked
eclines in the incidence of myocardial infarction (MI) were
oted from 1979 to 1994 in younger men as compared with
n increased incidence in older women (16).
Supplementary evidence has observed substantial delays
n health care seeking behavior, less intensive resource use
atterns, and longer times to diagnosis for women as
ompared with men (1,2,17–22). Although a reduced in-
ensity of care may be, in part, related to a differential
linical history, symptom profile, and acuity of presentation,
nderrecognition of disease in women may also be contrib-
tory to worsening outcome, especially for women with an
stablished diagnosis of IHD or acute MI (1,2,23–26). Of
he 1.1 million hospitalizations for acute MI each year,
ore men are admitted through varying age groups
721,000 in men vs. 410,000 in women), with differences
arrowing in elderly cohorts (2). Despite more male admis-
ions, the one-year death rate and rate of reinfarction is
igher in women (2). Notably, black women have a higher
ate of first heart attack than white women for those age 45
o 74 years (2). Symptomatic women, furthermore, have
ersistent, frequently refractory chest pain requiring more
ospitalizations than for men but also with lower ratings of
eneral well-being, more frequent reports of anxiety or
epressive symptoms associated with their disorder, and
ignificant limitations in their ability to perform activities of
aily living (27,28).
Compounding the challenge of female patients with a
ower quality of life and greater symptom burden is the
requent reporting that women presenting for the diagnostic
valuation of chest pain symptoms have “excellent survival”
29–31). Of this symptomatic cohort, they more often have
nsignificant or non-obstructive coronary disease or less
ubclinical disease (22–37). As recently reported in the
merican College of Cardiology’s National Cardiovascular
ata registry in 375,886 patients referred for diagnostic left
eart catheterization (45% women), the prevalence of ob-
tructive coronary disease was less in women across all age
50 to 80 years) groups (35). From this registry, the
revalence of significant obstructive coronary artery disease
i.e., stenosis 50%) ranged from 27% to 64% for women
Abbreviations and Acronyms
C-IMT carotid intima-media thickness
CT  computed tomography
FMD  flow-mediated dilation
IHD  ischemic heart disease
LV  left ventricular
MI  myocardial infarction
NRMI  National Registry of Myocardial Infarctionnd 45% to 87% of men ages 50 to 80 years of age, (espectively (p 0.0001 for all age subsets). Similar findings
re reported for coronary angiography performed for acute
oronary syndromes (38), and, thus, women are less likely to
enefit from clinical risk reduction algorithms focusing on
oronary revascularization strategies (39,40).
ENDER-SPECIFIC ISSUES RELATED TO ARTERIAL
IZE AND ATHEROSCLEROTIC DISEASE BURDEN
ecent innovations in cardiovascular imaging have revealed
differential event-free survival in women with vascular
maging abnormalities by computed tomography (CT),
agnetic resonance, or retinal photography (41,42). Al-
hough the prevalence of atherosclerosis measured by these
maging abnormalities for women lags behind that in men
similar to IHD rates), evidence that the combination of
maller arterial size, potentially more prominent positive
emodeling, and a greater role of the microvasculature (as
oted by evidence using carotid artery intima-media thick-
ess [C-IMT], retinal artery narrowing, or coronary calci-
cation) carry a greater prognostic weight in women as
ompared with men (41–48); more details on the role of the
icrovasculature will be discussed in part III of this review.
or example, any given extent of coronary calcification using
he Agatston score is associated with worsening mortality in
omen as compared with men (41). This score does not
onsider arterial size but only coronary calcium extent and is
ssociated with relatively greater mortality rates for women
ompared with men. Smaller arterial size contributes to
ower rates of success with revascularization strategies and
ore frequent angina (49,50).
ROGNOSIS IN ENDOTHELIAL DYSFUNCTION
he prognostic value on coronary and peripheral endothelial
unction testing is compiled in Figure 1. In synthesizing the
5 published reports on coronary and peripheral testing for
ndothelial dysfunction, the overall relative risk ratio for
bnormal findings is elevated nearly 10-fold (95% confi-
ence interval [CI] 7.8 to 12.8) (51–65). Recent evidence
uggests that the relationship between endothelial dysfunc-
ion and outcome may be mediated by other factors such as
he extent of atherosclerotic disease burden (66,67). Of
omen who are at highest risk, preliminary evidence sug-
ests that chronic hyperglycemia results in markedly re-
uced endothelium-dependent and -independent coronary
asodilator function (68).
These results are important because restoration of endo-
helial function is associated with improved outcomes
69,70). In a recent clinical study of 400 hypertensive,
ostmenopausal women, improvement in flow-mediated
ilation (FMD) (10% relative to baseline) of the brachial
rtery, using high-resolution ultrasound, was associated
ith a 7.3-fold lower rate of cardiovascular events when
ompared with women with 10% improvement in FMD
69). A recent report also noted no significant improvement
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February 7, 2006:21S–9S The WISE Study: Microvascular and Macrovascular Diseasen FMD with selective estrogen receptor modulation with
aloxifene in postmenopausal women (71).
Gender-specific differences in the process of risk factor
njury and atherosclerotic responses may explain the fre-
uency and significance of chest pain symptoms in women.
hile the etiology and genesis of chest pain symptoms in
omen is currently not well understood, a number of
ypotheses are suggested. We postulate that decades of
elatively higher levels of inflammation, coupled with a
lustering of risk factors that occurs with a loss of estrogen
uring menopause, may be associated with more frequent
ndothelial dysfunction, a loss of arterial compliance, and
ysfunction in the microvasculature, resulting in myocardial
ow heterogeneity more frequently in women. Evidence
rom intravascular ultrasound and autopsy data support the
ole of sex-hormone-mediated positive remodeling in
omen whereby greater atherosclerotic storage may be
romoted minimizing luminal intrusion of plaque (72–76);
similar phenomenon has been reported after cardiac
ransplantation (77). Although described simplistically here,
t is possible that there are multiple types of atherosclerotic
iseases with varying pathophysiologic pathways, one of
hich is particular for our female patients.
IAGNOSTIC VERSUS
ROGNOSTIC RISK ASSESSMENT
he longstanding patient management approach for IHD
as been to utilize an array of diagnostic tools that estimate
he likelihood of “culprit” obstructive coronary lesions as the
tiology for provoking ischemia and patient symptoms. This
trategy is expected to be less effective in women with a
reater prevalence of non-obstructive coronary disease and a
igher frequency of myocardial ischemia, and indeed it is.
igure 1. Forest plot of the summary relative risk for major adverse card
ummary relative risk ratio is elevated 11.1- and 10.0-fold for evidence ofn alternative strategy would rely upon the estimation of (he “culprit patient” or prognosis, and, thus, any test that
rovides independent prognostication in women might be
sed. Therefore, a shift in reliance upon prognostic risk
ersus diagnostic obstructive lesion detection may be par-
icularly helpful in women, especially in minimizing the role
f disease-based terminology such as “false positive” test
esults. A synthesis of evidence suggests that accurate risk
ssessment is possible with conventional testing including
easures of functional capacity, plaque burden, extent and
everity of perfusion abnormalities, global ventricular func-
ion measurements, as well as with inflammatory markers.
or example, as based upon the current evidence, the
rognostic value of either stress echocardiography or single-
hoton emission computed tomography imaging reveals
hat a high risk scan is associated with a 10-fold increased
isk of cardiac death or MI (78). An optimal non-invasive
isk model may include, in addition to the use of a global
isk score that includes traditional risk markers, measures of:
) ventricular function; 2) regional flow or perfusion; 3)
etabolism or energy requirements (e.g., 31P-magnetic
esonance spectroscopy or positron emission tomography
stimates of aerobic metabolism); and/or 4) vessel wall
bnormalities (e.g., C-IMT, electron beam tomography, or
etinogram) and markers of inflammation (41–44,79). Pre-
ictive models may also be improved by the addition of
arkers of left ventricular (LV) hypertrophy because the
ttributable mortality risk is greater in women than men
80).
ENDER-SPECIFIC ISSUES IN
BSTRUCTIVE CORONARY DISEASE
n approximately 60% of cases, the initial presentation of
HD in women is acute MI or sudden cardiac death
ents in women with coronary or peripheral endothelial dysfunction. The
ary and peripheral endothelial dysfunction. CI  confidence interval.2,81–84). For the women initially presenting with a fatal
i
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The WISE Study: Microvascular and Macrovascular Disease February 7, 2006:21S–9Sschemic event, there are morphologic differences in the
tiology for sudden cardiac death by age and gender
72–76). Plaque rupture found as sudden cardiac death
ost-mortem typically occurs with a large necrotic core and
isrupted fibrous cap infiltrated by macrophages and lym-
hocytes in men and older women. By comparison, younger
omen have a greater tendency toward plaque erosion
here a fibrous cap is absent at the plaque erosion site and
he exposed intima consists predominantly of smooth mus-
le and proteoglycans (Fig. 2). In a recent autopsy series,
omen also had a greater frequency of distal microvascular
mbolization in the setting of a fatal epicardial thrombosis
s compared to men (76). This greater rate of embolization
as independent of type of thrombus or the presence of
ecrosis.
The higher frequency of plaque erosion in women as
ompared to more plaque explosion in men may contribute
o the higher mortality noted for younger women when
ompared with age-matched men (18,19), although this
elationship may be confounded when considering the
tiology of pre-hospital deaths. Other data sets demonstrate
hat among patients undergoing urgent coronary angiogra-
hy for acute coronary syndromes, women have a higher
revalence of non-obstructive coronary arteries resulting in
igure 2. An example of plaque erosion, the typical presentation for sudden
ubocclusive thrombus in multiple views and sections (a to d) in a 58-yeaiagnostic uncertainty and therapeutic indecision and delays d27,38). Additionally, the relatively higher IHD mortality in
omen may also be related to a relatively greater burden of
therosclerosis in relation to the degree of positive arterial
emodeling, possibly due to sex-hormone-modulated ath-
rosclerotic storage.
The prevalence of the obstructive coronary disease is
elatively low in premenopausal women with disease prev-
lence of approximately 5% for those 35 years of age. The
revalence of obstructive coronary disease increases dramat-
cally for a woman after age 50 and ranges from 14%, 29%,
8%, 65%, and 79% for women ages 35 to 44, 45 to 54, 55
o 64, 65 to 74, and 75 years, respectively (2,81). A major
ovariate for obstructive coronary disease prevalence is the
resence of symptoms where non-anginal, atypical, and
ypical angina increase with the prevalence of obstructive
oronary disease from 6% to 57% (2,81–84). After sudden
ardiac death, the most common presentation of obstructive
oronary disease for women is atypical symptoms including
atigue, shortness of breath, and atypical chest pain
3,19,36,44,85). Despite a moderately strong relationship in
his ranking, the correlation of symptoms with obstructive
oronary disease is less accurate and less precise in women
han for men (85).
In the setting of acute or chronic obstructive coronary
ac death in younger women. This example reveals an eccentric plaque with
female smoker. Reproduced with permission (75).isease, women have an overall worse prognosis than men
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February 7, 2006:21S–9S The WISE Study: Microvascular and Macrovascular Disease2,18,19,21,22,83,84,86–94). In particular, near-term prog-
osis for women appears to be driven by the acuity of
resentation and the degree of comorbidity (94). Younger
omen presenting with acute MI are also at particularly
igh risk of death, as recently reported in the National
egistry of Myocardial Infarction-2 (NRMI-2) database, in
art due to comorbidity, infarct severity, and medical
anagement differences (Fig. 3) (18). In this NRMI-2
atabase of 384,878 (40% women) patients, the odds ratio
f death was increased 11% for every five-year decrement in
ge in the women. When outcomes were adjusted for
omorbidity, infarct severity, and medical management
ifferences, only one-third of the variability in worsening
utcome could be explained among the women. This notion
f a high-risk younger female cohort further demonstrates
ur lack of understanding of gender-related differences in
utcome (18).
There are clear differences in outcomes for women
dmitted with acute coronary syndromes as compared to
hose evaluated with stable chest pain symptoms. For
omen with stable chest pain symptoms, overall cardiac
urvival is superior to men (29–31). In those women
resenting with acute MI, however, the one-year death and
einfarction rates are higher in women (2,81). Variability in
utcome is related to comorbidity, infarct severity, and
anagement intensity; however, the majority of the gender
ap is currently unexplained (18–20). Women presenting
ith unstable symptoms are more frequently found to have
on-obstructive coronary arteries and non–Q-wave MIs,
uch that aggressive revascularization management strate-
ies have not been found to be effective, compared to a clear
enefit among the men. Indeed, with revascularization,
igure 3. This graph shows the annual rate of first myocardial infarction (
s compared with women. Despite the differences in the rate of myocardial i
omen. In an adaptation of the result from Vaccarino et al. (18), the odds r
nd elevated 1.6-fold for women in the 45-to-54-year range.omen paradoxically have similar long-term adverse out- nome rates to the men, despite having less extensive and
evere obstructive coronary disease, better LV function, and
igher rates of “normal” coronary arteries, all of which
hould portend a relatively better outcome (22).
With and without obstructive coronary disease, women
re more frequently admitted for congestive heart failure
ymptoms with preserved LV function as compared to men,
lthough recent reports note a probable decreasing inci-
ence in women but not men (91,95,96). In the Framing-
am study, Levy et al. (95) note a decreasing incidence that
ay be related to a reduction in diastolic dysfunction and
mproved hypertension detection and management in
omen (especially in the postmenopause) (96).
Paradoxically, while women are more likely to be admit-
ed for congestive heart failure with preserved LV function
han men, they are more likely to die (2), suggesting a
otential misunderstanding of disease heart failure patho-
hysiology and treatment in women. Notably, this is also
rue both with and without obstructive coronary disease.
fter coronary bypass surgery, operative mortality is higher
or women (n 441,542 patients enrolled in the Society for
horacic Surgery database [28% women]; operative mortal-
ty  4.0% for women and 3.2% for men, p  0.0001) (97),
n part due to excessive rates of congestive heart failure
38,97–99). Similar findings are observed in angioplasty
egistry data (86–88). Additionally, of those with heart
ailure symptoms, women are more likely to have a lower
uality of life with more frequent depression when com-
ared with men (100).
After medical stabilization and a pathway that includes
gender-neutral” aggressive intervention, the long-term out-
ome after percutaneous coronary interventions and coro-
y gender noting the significantly higher rate across all age groups in men
ion by gender, post-infarction mortality is elevated significantly in younger
as elevated approximately two-fold for women in the 35-to-44-year rangeMI) b
nfarctary bypass surgery appears similar by gender (86,88,89,97–
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The WISE Study: Microvascular and Macrovascular Disease February 7, 2006:21S–9S9). Of concern, however, women receive relatively less
ymptom relief with revascularization procedures compared
o men, in terms of persistent symptoms, evidence of
schemia, and reduced functional capacity (12,82). How-
ver, women have a more difficult recovery after coronary
ypass surgery (101). As compared with men, women start
ith and exhibit a greater decline in physical functioning
nd depressive symptoms. In this recent report by Vaccarino
t al. (101), the more difficult recovery was not explained by
aseline illness severity, health status, or other clinical
actors.
UMMARY POINTS FOR IHD IN WOMEN
he data reviewed here lead to a number of summary points
ith regard to IHD in women:
. Traditional diagnostic tests that focus on identifying
obstructive disease do not work as well in women
compared to men. Indirect evidence reviewed here
suggests that prognostic risk assessment (e.g., detection
of the culprit patient) may work relatively better than
diagnostic obstructive coronary disease assessment (e.g.,
detection of the culprit stenosis) for women. Future
investigation should be aimed at testing this strategy.
. The “typical” female presentation of signs and symp-
toms of IHD is more complex and multifactorial than
that of men. Evidence reviewed here suggests that
additional risk assessment (blood inflammatory markers,
evidence of plaque burden, and evidence of ischemia)
may be of relatively greater importance in women due to
this diagnostic uncertainty. Future efforts should be
directed at exploring new risk assessment paradigms in
women.
. Although men and women face relatively similar tradi-
tional cardiac risk factor loads, there may be gender-
specific differences in response to this atherosclerotic
risk burden. In particular, differences in inflammatory
response, possibly mediated by reproductive hormones,
and specifically estrogen deficiency in premenopausal
women, may be etiologic in subsequently observed
differences in IHD presentation, pathophysiology, and
responses to treatment. Greater understanding of these
gender-specific pathophysiological processes in women
is needed.
. Persistent signs and symptoms of IHD in the setting
of non-obstructive coronary disease is a significant
health problem for women, and appears to be related
to vascular dysfunction. Data now demonstrate that
the magnitude of this problem rivals the prevalence
and cost of female-specific cancers, and that it is
associated with a diminished event-free survival. Lit-
tle is known regarding diagnostic and therapeutic
approaches. Investigation furthering our understand-
ing of the disease pathophysiology, diagnosis, and
therapeutic strategies is needed. s. Estrogen deficiency due to anovulatory menstrual cy-
cling appears to be prevalent in premenopausal women
with signs and symptoms of ischemia and is adversely
associated with obstructive coronary disease, and may be
etiologic for obstructive coronary disease during the
postmenopausal years. Indirect evidence reviewed here
suggests the hypothesis that estrogen deficiency may be
a contributor to the observed more adverse outcomes in
premenopausal women compared to age-matched men
with IHD. Future investigation should be aimed at
understanding both the premenopausal etiologic ante-
cedents of IHD observed later in the postmenopausal
years, and the relatively more adverse outcomes ob-
served in these younger women, such that therapeutic
strategies can be developed.
EW HYPOTHESES IN THE
ATHOPHYSIOLOGY OF IHD IN WOMEN
ecent lines of evidence indicate that sex hormones play
role in the development of IHD in women. Endoge-
ous and exogenous sex hormones influence fat distribu-
ion/deposition, insulin resistance, lipid metabolism, co-
gulation factors, and inflammation measured by high
ensitivity C-reactive protein. We propose that vascular
ysfunction, in the absence of obstructive disease, is
enerally more prevalent in women as compared to men,
ue to these sex hormone differences, and is manifest by
ore frequent symptoms and evidence of provocative
schemia or altered metabolism. Because of this gender-
pecific link, we also hypothesize that vascular dysfunc-
ion is more frequently present in women with obstruc-
ive coronary disease, and may, therefore, contribute to
he higher adverse outcomes also experienced by this
roup as compared with men.
In this expanding definition of the “typical female”
HD pathophysiology, vascular dysfunction plays a cen-
ral role as the genesis of symptoms and ischemia as well
s a global estimator of outcome (including “soft”
ymptom-based events). We further postulate that isch-
mia in the setting of vascular dysfunction places a
oman at relatively higher risk than her male counter-
arts for any amount of obstructive coronary disease.
hese women with ischemia consistently have less symp-
om relief with current therapies primarily because the
athophysiology is not well understood. This latter point
urther supports the role of ischemia due to vascular
ysfunction as a source for symptoms and being the
rimary determinant of outcome. We propose that symp-
oms occur in stressful settings due to impaired flow
eserve and endothelial dysfunction among vessels with a
elatively smaller arterial lumen, which results in myo-
ardial ischemia. This latter point may be further exac-
rbated in the setting of insulin resistance, the metabolic
yndrome, or hypertensives with diastolic dysfunction,
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enopausal women.
EVELOPING INVESTIGATIVE STRATEGIES
OR IMPROVED IHD RISK ASSESSMENT AND
HERAPEUTIC INTERVENTIONS FOR WOMEN
rom multiple lines of evidence reviewed herein, it appears
hat ischemia due to vascular dysfunction plays an important
ole in the genesis of IHD in women, placing the culprit
esion strategy as incomplete for diagnosis, estimation of
rognosis, and treatment of female patients. Piecing to-
ether the unfolding observational evidence on women with
uspected IHD has been the focus of several researchers but
ost prominently that of the National Institutes of Health-
ational Heart, Lung, and Blood Institute-sponsored
omen’s Ischemia Syndrome Evaluation (WISE) study.
ritical areas of investigation for improving IHD detection
nd treatment include:
. Study of a wider berth of symptoms, functional disabil-
ity, and quality-of-life indicators that are abnormal but
do not clearly define a “typical” presentation
. Additional symptom assessment combined with tradi-
tional and novel risk factors as well as stress-induced
cardiac imaging ischemic markers to provide an im-
proved risk assessment in women
. Further inquiry as to whether women with diminished
functional capacity, evidence of myocardial ischemia, or
vascular dysfunction should be considered “at-risk” even
in the absence of obstructive coronary disease
. New imaging techniques that may more clearly docu-
ment the diagnosis of ischemia due to vascular dysfunc-
tion, and facilitate the development of new treatment
approaches
. Inquiry assessing the role gender-specific reproductive
hormones play in IHD etiology, pathophysiology, diag-
nostic and prognostic assessment, and therapeutic
response
In summary, this review puts forth an alternative, yet
ore complex, hypothesis for IHD in women that considers
oth novel and traditional risk factors, as well as new
pportunities in cardiovascular imaging. This new paradigm
or the evaluation of women requires additional research to
ssure its further development and validation. Through
esting of these new hypotheses, we hope that new treat-
ent paradigms may be designed to improve outcomes for
omen with IHD.
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